Suraksha Diagnostics reported a strong Q1 FY27, with revenue up 21% to Rs 88.7 crore and net profit rising 40% to Rs 12.8 crore. The company successfully turned its newly established centers EBITDA positive, marking a significant milestone in its expansion strategy. Investors should track the company's network growth in Eastern India and its expanding genomics segment.
Suraksha Diagnostics Ltd. reported robust financial results for the first quarter of fiscal year 2027, highlighting improved operational efficiency across its network. The company’s consolidated revenue grew 21% year-on-year to Rs 88.7 crore, while its profit after tax (PAT) jumped 40% to Rs 12.8 crore. Operating profit (EBITDA) also saw a healthy rise of 28% to Rs 31.5 crore, reflecting improved margins.
A key highlight of this quarter was the performance of the company's newer diagnostic centers. Typically, diagnostic chains face margin pressure when opening new locations, but Suraksha Diagnostics reported that centers operational for less than two years achieved EBITDA positivity for the first time, recording a 6.5% margin. In comparison, its mature centers, which have been running for over two years, maintained strong profitability with a 40.9% EBITDA margin. This shift suggests that the company is effectively managing the costs associated with its rapid network growth.
The diagnostics chain currently operates 72 centers. Its expansion strategy is moving beyond its home market of West Bengal, with new hubs recently added in Jharkhand and plans underway for a facility in Tripura. Alongside its core pathology business, the company is seeing rapid growth in its genomics division, which reported a 136% year-on-year revenue increase to Rs 1.37 crore. The management has set a target to reach 100 centers by fiscal year 2028.
The company also announced a final dividend of Rs 0.50 per share. Investors should note that the record date for this dividend is September 15, 2026.
While the company has shown strong growth, investors should consider the broader risks in the diagnostics sector. Competition is intensifying as both established and newer players expand their presence in various regions. Additionally, as the company pushes toward its goal of 100 centers, the execution risk—including potential delays in setting up new hubs or the challenge of maintaining profitability in untested markets—remains a factor to watch. Future margins will also depend on the company's ability to manage costs amidst this expansion phase.
The stock market reacted positively to the earnings report, with the share price rising approximately 12.6% on August 13, 2026, following the release of the results. It has since stabilized around the Rs 308 level as of August 20, 2026. The next important monitorables for stakeholders include the progress of the upcoming Tripura hub and the sustainability of EBITDA margins across the newly opened centers.